Chapter 30 Agents Used to Treat Parkinson’s Disease.

Slides:



Advertisements
Similar presentations
1 Adult Health II Neurological Diseases Jerry Carley RN, MSN, MA, CNE Summer, 2010.
Advertisements

Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
Diagnosis and Management of Parkinson’s Disease
ILOs At the end of this lecture you will be able to:- Recognize the symptoms and pathophysiology of parkinsonism. Understand the pharmacology of drugs.
ILOs At the end of this lecture you will be able to:- Revew the symptoms and pathophysiology of parkinsonism. Detail on the pharmacology of drugs used.
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
Drugs for Parkinson’s Disease & Psychotherapeutics NSG 106 Pharmacotherapeutics.
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Presented by Abdulaziz .M. Al-Saad
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
Initial Diagnosis and Management of Parkinson’s Disease
Parkinson’s Disease Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Anticonvulsants and Antiparkinsonism Drugs Chapter 5.
Cathy Chuang, MD Jacobi Medical Center Department of Neurology
Anti-Parkinson Drugs Dr Gareth Noble.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Antiparkinsonian Drugs.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Objectives Description of Parkinson's disease
Drugs for Parkinon’s disease Parkinson's disease –progressive tremor –Bradykinesia and rigidity –degeneration of the dopaminergic nigrostriatal pathway.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Chapter 31 Anti-Parkinson Agents. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Parkinson’s.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Drugs For Parkinson's Disease. History of Parkinson's Disease l First characterized in 1817 by James Parkinson : An Essay On The Shaking Palsy.
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Drugs used in Parkinson disease. Epidemiology Average age of onset 62.5 Men and women affected equally Genetic Link African-Americans and Asians less.
Benjamin L. Walter M.D. Medical Director, Deep Brain Stimulation Program Neurological Institute University Hospitals Case Medical Center Management of.
Represented by SHIVAJI SINGH SAMEER CHAVAN SOURIMA MUKHERJEE SONAL KULKARNI SUVARNA CHAVAN M.Sc (CLINICAL RESEARCH) (CRANFIELD)GROUP-9.
Parkinson’s Disease Dr. Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.
Slide 1 Mosby items and derived items © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 15 Drugs Used for Parkinson’s Disease.
Drugs used in parkinsonism
By Prof. Hanan Hagar Pharmacology unit Medical College.
RLS Slide Library Version All Contents Copyright © WE MOVE 2001 Restless Legs Syndrome: Classification, Diagnosis and Approaches to.
By Prof. Hanan Hagar Pharmacology unit Medical College.
1 Copyright © 2012, 2009, 2006, 2003 by Saunders, an imprint of Elsevier Inc. Chapter 23 DRUGS FOR NEUROLOGIC DISORDERS: PARKINSONISM AND ALZHEIMER’S DISEASE.
Parkinson's Disease ILOs
Drugs in parkinsonism ilos
Dr. Laila M. Matalqah Ph.D. Pharmacology PHARMACOLOGY OF CNS part 1 General Pharmacology M212.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
CNS -Antiparkinsonian Drugs Discuss the signs and symptoms exhibited by a patient with Parkinson’s Disease Describe the actions and intended effects of.
 Parkinson’s disease is a neurodegenerative disorder first described by Dr James Parkinson, a London physician, in The underlying cause is loss.
Drugs used in Parkinson’s disease. Understand the epidemiology, basic pathophysiology and impact of Parkinson’s Disease (PD). Identify the clinical features.
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Pharmacological Treatment of Parkinson Disease: A.
항 파킨슨씨 약물 Anti-Parkinson Drug.
Drugs for Degenerative Diseases of the Nervous System.
Drugs used in Parkinson disease Historical Perspective Dr. James Parkinson ( ) 1817 “ involuntary tremulous motion ” “ pass from a walking.
Drug Therapy for Parkinson’s Disease
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Drugs used in Parkinson’s disease
Parkinson's disease.
Drugs Used for Parkinson’s Disease
Parkinsonism.
Drugs for Neurologic Disorders: Parkinsonism and Alzheimer’s Disease
Drugs of Anti-Parkinson’s disease
Central Nervous System Drugs: Part 1 Autonomic Nervous System Drugs Drugs Used to treat Seizures Drugs Used to treat Parkinson’s Disease Analgesics.
Lecture 3 Dr.Narmin Hussen
Drugs for Parkinson’s Disease
Jeopardy Final Jeopardy Barbiturates $100 $100 $100 $100 $100 $200
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
Central Nervous System
מחלת פרקינסון מחלת פרקינסון היא מחלה Progressive.
Anti-parkinsonism Drugs
Anti-parkinsonism Drugs
Introduction to Clinical Pharmacology Chapter 28 Antiparkinson Drugs
Drugs for Degenerative Diseases of the Nervous System
Classification of Epilepsy (p. 227)
Chapter 17 Antiparkinson Drugs.
Introduction to Clinical Pharmacology Chapter 28 Antiparkinson Drugs
Presentation transcript:

Chapter 30 Agents Used to Treat Parkinson’s Disease

2 Parkinson’s Disease A neurological disorder characterized by: Muscle tremors Muscle rigidity Lack of coordination Drooling Shuffling gait Postural changes

3 Parkinson’s Disease Slow onset – several months to years Approximately 1 million Americans affected Usually develops between the ages of Women and men equally affected Family history not a factor Progressive disease, if not treated causes death Cause is not completely understood

4 Parkinson’s Disease Imbalance of dopamine and acetylcholine levels in the brain Levels of other neurological chemical decrease: Gamma-aminobutyric acid (GABA) Serotonin Norepinephrine

5

6 Classes of Anti-Parkinson Agents Dopaminergic agents Catechol-O-methyltransferase inhibitors Cholinesterase inhibitors Anticholinergic agents

Classes of Anti-Parkinson Agents Non-ergot dopamine agonists (direct- acting dopamine receptor agonists) May be classified as “dopaminergic” Indirect-acting dopamine receptor agonists (monoamine oxidase inhibitors, or MAOIs) Also can be classified as “dopaminergic” 7

8 Dopaminergic agents Levodopa prototype Most effective drug treatment Acts peripherally Rapidly converts to dopamine Symptoms subside or disappear

9 Levodopa Therapeutic effects Therapeutic intensity varies Dosage dependent Adverse effects Nausea and vomiting Orthostatic hypotension Cardiac arrhythmias

10 Carbidopa/Levodopa (Sinemet) Carbidopa prevents levodopa from being broken down in the peripheral circulation Improves neurological-skeletal muscle activity Combining these agents reduces the required Levodopa dose by 25% Carbidopa, 10 mg / Levodopa,100 mg dose

11 Amantadine (Symmetrel) Anticholinergic/dopaminergic in action Treats viral disorders such as influenza Acts as an anti-Parkinson agent; it exerts an additive effect on Levodopa Increases CNS dopamine concentration

Other dopaminergic anti-PD drugs Parlodel (bromocriptine mesylate) Ergot derivative; may allow reduced maintenance levodopa dosage Mirapex (pramipexole dihydrochloride) Nonergot; treats tremors, shaking, slow movements Also treats restless leg syndrome Can cause hypotension – teach slow position transition 12

Other dopaminergic anti-PD drugs Requip and RequipXL (ropinirole) Also treats RLS Lowers B/P Neupro (rotigotine) patch Nonergot; treats early-stage PD Sleep attacks 13

Other dopaminergic anti-PD drugs Zelapar (selegiline HCl) Indirect-acting dopamine receptor agonist /monoamine oxidase inhibitor Patch developed for antidepressant (Emsam) MAOIs – high risk of interaction with other medications Check for contraindications 14

15 Newest class of anti-Parkinson drug agents Treats clients with history of poor response to levodopa Sustains dopaminergic levels Brain remains stimulated Catechol-O-Methyltransferase Inhibitors

16 Catechol-O-Methyltransferase Inhibitors Adverse effects Liver failure Dyskinesia Orthostatic hypotension Dystonia Somnolence GI irritation Note interactions with other drugs

Catechol-O-Methyltransferase Inhibitors Adjuncts to levodopa Comtan (entacapone) Many interactions with other drugs Tasmar (tolcapone) Liver damage 17

Cholinesterase inhibitors Exelon (rivastigmine) – origin as Alzheimer’s drug (see Ch. 28) Apokyn (apomorphine HCl) SQ “rescue” drug for undermedicated, “frozen” state. Four- to eight-minute onset give with antiemetic r/t morphine; not analgesic, no dependency risk 18

19 Anticholinergic Agents Reduces excessive cholinergic brain activity Example: trihexyphenidyl (Artane) Used for clients with minimal symptoms Adjunct with other agents  Caution: narrow-angle glaucoma

Anticholinergic Agents Inhibit acetylcholine in PNS Cogentin (benztropine mesylate) Akineton (biperiden HCl) Kemadrin (procyclidine) Adjunct agents Use with minimal symptomsS 20

21 Adverse Effects of Anticholinergics Dry mouth Urinary retention Constipation

22 Nursing Considerations Patients on levadopa (not Sinemet) should not take vitamin B6 Educate patient on disease process, medication therapy goals, and adverse effects and what to do about them Assure adequate fluids Counsel patients to be careful when doing activities that require alertness

Nursing Considerations Assess for need for other supportive therapies such as physical, occupational, and speech High protein food may decrease absorption of levadopa Assess patients self care abilities on an ongoing basis Assess fall risk on an ongoing basis 23